^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    oxaliplatin

    i
    Other names: 1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA cross linking agent
    Related drugs:
    20h
    A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov)
    P1, N=102, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
    21h
    Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2029 --> Mar 2031 | Trial primary completion date: Dec 2029 --> Mar 2028 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • oxaliplatin • irinotecan • leucovorin calcium • Visudyne (verteporfin) • fluorouracil topical
    23h
    ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov)
    P2, N=143, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression • CLDN18.2 positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)
    1d
    Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Ming Liu
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    2d
    PROPERTY: Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy (clinicaltrials.gov)
    P=N/A, N=73, Completed, Nantes University Hospital | Active, not recruiting --> Completed | N=110 --> 73
    Trial completion • Enrollment change
    |
    oxaliplatin
    2d
    TFLAG: TAIC FOLFOX for Locally Advanced G/GEJA (clinicaltrials.gov)
    P2, N=31, Recruiting, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    New P2 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    2d
    Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis. (PubMed, Front Oncol)
    This phase II study (ChiCTR2300077718) aimed to assess the efficacy and safety of balloon-occluded HAIC (bHAIC) based on the FOLFOX (oxaliplatin plus fluorouracil and leucovorin) regimen (bHAIC-FO) in unresectable HCC. bHAIC-FO demonstrates encouraging efficacy and acceptable safety profiles in unresectable HCC treatment, particularly in treatment-naive patients. www.chictr.org.cn, identifier ChiCTR2300077718.
    Clinical • P2 data • Journal
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    2d
    D9803C00001: A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus. (2024-519787-40-00)
    P2/3, N=126, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    2d
    Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=50, Completed, Massachusetts General Hospital | Unknown status --> Completed
    Trial completion
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=71, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • TQB2930
    3d
    Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Salvianolic Acid B in Reversing Oxaliplatin Resistance of Colorectal Cancer Cells. (PubMed, IET Syst Biol)
    In conclusion, SalB modulates CRC drug resistance through multiple targets and pathways. SalB potentially reverses oxaliplatin resistance in CRC cells by regulating the ROS-mediated apoptotic signalling pathway.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9)
    |
    oxaliplatin
    3d
    EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Shanghai EpimAb Biotherapeutics Co., Ltd.
    New P1 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • bafisontamab (EMB-01)